VGI Trugene HIV-1 Test Downclassification Petition Anticipated By August
This article was originally published in The Gray Sheet
Executive Summary
Visible Genetics, Inc. plans to submit a petition to FDA by August seeking classification of its Trugene HIV-1 genotyping test and OpenGene DNA sequencing system as Class II following FDA's rejection of a September 2000 510(k) submission.